Compare Cadila Healthcare with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs FRESENIUS KABI ONCO. - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE FRESENIUS KABI ONCO. CADILA HEALTHCARE/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 32.6 22.1 147.2% View Chart
P/BV x 4.2 3.1 134.1% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 CADILA HEALTHCARE   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-19
FRESENIUS KABI ONCO.
Mar-13
CADILA HEALTHCARE/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs432176 245.7%   
Low Rs30679 390.3%   
Sales per share (Unadj.) Rs128.637.7 341.3%  
Earnings per share (Unadj.) Rs18.55.1 364.1%  
Cash flow per share (Unadj.) Rs24.46.7 362.8%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs101.542.5 238.5%  
Shares outstanding (eoy) m1,023.74158.23 647.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.93.4 85.1%   
Avg P/E ratio x19.925.0 79.7%  
P/CF ratio (eoy) x15.118.9 80.0%  
Price / Book Value ratio x3.63.0 121.7%  
Dividend payout %18.90-   
Avg Mkt Cap Rs m378,17020,135 1,878.2%   
No. of employees `00012.41.2 1,079.7%   
Total wages/salary Rs m21,241703 3,020.6%   
Avg. sales/employee Rs Th10,585.05,176.2 204.5%   
Avg. wages/employee Rs Th1,707.8610.4 279.8%   
Avg. net profit/employee Rs Th1,526.5699.6 218.2%   
INCOME DATA
Net Sales Rs m131,6565,963 2,207.9%  
Other income Rs m2,01118 11,172.2%   
Total revenues Rs m133,6675,981 2,234.9%   
Gross profit Rs m29,7311,430 2,078.9%  
Depreciation Rs m5,986258 2,321.1%   
Interest Rs m1,935-26 -7,442.3%   
Profit before tax Rs m23,8211,216 1,958.6%   
Minority Interest Rs m4690-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m5,303342 1,549.7%   
Profit after tax Rs m18,987806 2,356.0%  
Gross profit margin %22.624.0 94.2%  
Effective tax rate %22.328.1 79.1%   
Net profit margin %14.413.5 106.7%  
BALANCE SHEET DATA
Current assets Rs m84,9815,102 1,665.8%   
Current liabilities Rs m73,4252,385 3,078.1%   
Net working cap to sales %8.845.6 19.3%  
Current ratio x1.22.1 54.1%  
Inventory Days Days75150 49.7%  
Debtors Days Days110113 96.7%  
Net fixed assets Rs m133,4935,148 2,593.1%   
Share capital Rs m1,024158 647.3%   
"Free" reserves Rs m102,8396,556 1,568.7%   
Net worth Rs m103,8636,732 1,542.9%   
Long term debt Rs m39,497952 4,148.0%   
Total assets Rs m234,83110,388 2,260.6%  
Interest coverage x13.3-45.8 -29.1%   
Debt to equity ratio x0.40.1 268.8%  
Sales to assets ratio x0.60.6 97.7%   
Return on assets %8.97.5 118.7%  
Return on equity %18.312.0 152.7%  
Return on capital %18.314.6 125.3%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m48,4045,298 913.7%   
Fx outflow Rs m11,5931,772 654.2%   
Net fx Rs m36,8113,525 1,044.2%   
CASH FLOW
From Operations Rs m28,8231,274 2,262.2%  
From Investments Rs m-57,387-1,204 4,765.6%  
From Financial Activity Rs m18,846-196 -9,610.4%  
Net Cashflow Rs m-7,105-126 5,625.5%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 8.3 0.3 2,766.7%  
FIIs % 5.9 9.6 61.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 9.1 120.9%  
Shareholders   44,069 42,599 103.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   SHASUN PHARMA  WYETH  GSK PHARMA  ALEMBIC  DR. REDDYS LAB  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades 138 Points Lower; Dow Futures Down by 124 Points(12:30 pm)

Share markets in India are presently trading marginally lower. The BSE Sensex is trading down by 138 points, down 0.3%, at 40,566 levels.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Oct 9, 2020

How I picked an exciting stock using trends from both the commodity and equity markets.

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

The Inflection Point for Defence Stocks is Getting Closer(Profit Hunter)

Oct 9, 2020

Few Indian defence companies could use their engineering capabilities to eventually become global leaders.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Oct 22, 2020 02:30 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - SANOFI INDIA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS